Latest investigations into retatrutide peptide reveal significant outlook for managing weight and type 2 disease. The peptide, a dual activator of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide, seems to provide greater weight loss and glucose management compared existin